Gilead price target raised to $154 from $144 at BofA

Core Viewpoint - Bank of America has raised the price target for Gilead (GILD) to $154 from $144 while maintaining a Buy rating on the shares, indicating confidence in the company's growth potential [1] Summary by Category Price Target Adjustment - The price target for Gilead has been increased to $154 from $144, reflecting a positive outlook on the company's performance [1] Valuation Method Change - The firm has switched its valuation method, which may influence future assessments of the company's stock [1] Growth Drivers - Gilead's "steady" growth in its HIV franchise is considered core to the Buy thesis, with expectations of upside from recent and upcoming product launches [1]